echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Reduce postprandial hyperglycemia!

    Reduce postprandial hyperglycemia!

    • Last Update: 2022-04-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
      Recently, Zhejiang Medicine entered the administrative examination and approval stage with the miglitol orally disintegrating tablet, which was produced as a generic version of Class 3, and this product is temporarily blank in the domestic market
    .
    According to data from Minet.
    com, in 2020, the market size of miglitol in Chinese public medical institutions and physical pharmacies in Chinese cities will exceed 600 million yuan, a year-on-year increase of nearly 40%
    .
    Source: State Food and Drug Administration's official website Miglitol is an alpha-glucosidase inhibitor, which reduces postprandial hyperglycemia by inhibiting alpha-glucosidase and delaying the absorption of carbohydrates
    .
    At present, there is only one miglitol tablet that has been marketed in China.
    Shandong New Times, Zhejiang Pharmaceutical Xinchang Pharmaceutical Factory, and Sichuan Weiao Pharmaceutical have the production approval for miglitol tablets.
    The data from Minet.
    com shows that In 2020, the total market size of this product in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) and China's urban physical pharmacy terminals will exceed 600 million yuan, a year-on-year increase of nearly 40%
    .
    Research and development of new dosage forms of miglitol Source: MED2.
    0 China Drug Evaluation Database of Minet.
    com In terms of new dosage forms of miglitol, Zhejiang Medicine exclusively submitted the marketing application for miglitol orally disintegrating tablets under the new registration classification, and recently Enter the administrative approval stage
    .
    As one of the three major chronic disease drugs, diabetes drugs occupy an important position in the chemical drug terminal of physical pharmacies in China, among which non-insulin hypoglycemic drugs are the main ones
    .
    In recent years, sales of non-insulin hypoglycemic drugs for chemical drug terminals in Chinese urban physical pharmacies (unit: ten thousand yuan) Source: Minet The drug market size is about 6 billion yuan, accounting for more than 60% of the sales in the diabetes drug market
    .
    2021E China's urban brick-and-mortar pharmacy chemical terminal chemical drug terminal TOP5 non-insulin hypoglycemic drugs Product source: Minet China urban brick-and-mortar pharmacy terminal competition landscape The total market share of the non-insulin hypoglycemic drug TOP5 products is close to 50%, of which the new oral hypoglycemic drug Dag The sales growth rate of Liejing tablets (sodium-glucose cotransporter inhibitor) will be close to 60%, and the product ranking will rise from the seventh in 2020 to the fourth in 2021E
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.